Literature DB >> 29324459

Discordance between lipoprotein particle number and cholesterol content: an update.

Eric P Cantey1, John T Wilkins2.   

Abstract

PURPOSE OF REVIEW: The cholesterol content within atherogenic apolipoprotein-B (apoB) containing lipid particles is the center of consensus guidelines and clinicians' focus whenever evaluating a patient's risk for atherosclerotic cardiovascular disease. The pathobiology of atherosclerosis requires the retention of lipoprotein particles within the vascular intima over time followed by maladaptive inflammation resulting in plaque formation and rupture in some. The cholesterol content is widely variable within each particle creating either cholesterol-deplete or cholesterol-enriched particles. This variance in particle cholesterol content varies within and between individuals. Discordance analysis exploits this difference in cholesterol content of particles to demonstrate the differential significance of LDL-cholesterol (LDL-C) and non-HDL-C from measures of lipoprotein particle number in terms of assessing atherosclerotic cardiovascular disease risks. RECENT
FINDINGS: Three studies have added to the growing body of literature of discordance analysis. Despite wide variability of discordance cutoffs, baseline risk of atherosclerotic disease, and populations sampled, the conclusion remains the same: risk of atherosclerotic disease follows apoB lipid particle concentration rather than cholesterol content of lipid particles.
SUMMARY: In addition to traditional lipid fractions, assessments of atherogenic particle number should be strongly considered whenever assessing CVD risk in nontreated and treated individuals. There is a need for clinical trials that focus not only on the reduction in LDL-C but apoB, as well.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29324459     DOI: 10.1097/MED.0000000000000389

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  9 in total

1.  Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.

Authors:  Renato Quispe; Mohamed B Elshazly; Di Zhao; Peter P Toth; Rishi Puri; Salim S Virani; Roger S Blumenthal; Seth S Martin; Steven R Jones; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-07-10       Impact factor: 7.804

2.  Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Authors:  Karol M Pencina; George Thanassoulis; John T Wilkins; Ramachandran S Vasan; Ann Marie Navar; Eric D Peterson; Michael J Pencina; Allan D Sniderman
Journal:  J Am Coll Cardiol       Date:  2019-07-09       Impact factor: 24.094

Review 3.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

4.  A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.

Authors:  Maureen Sampson; Clarence Ling; Qian Sun; Roa Harb; Mohmed Ashmaig; Russell Warnick; Amar Sethi; James K Fleming; James D Otvos; Jeff W Meeusen; Sarah R Delaney; Allan S Jaffe; Robert Shamburek; Marcelo Amar; Alan T Remaley
Journal:  JAMA Cardiol       Date:  2020-05-01       Impact factor: 14.676

5.  LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China.

Authors:  Yanmei Lou; Xue Li; Liming Cao; Pei Qin; Jing Shi; Yanyan Zhang; Changyi Wang; Jianping Ma; Li Wang; Xiaolin Peng; Hongen Chen; Shan Xu; Fulan Hu; Yashuang Zhao; Ping Zhao
Journal:  Lipids Health Dis       Date:  2020-06-18       Impact factor: 3.876

6.  Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.

Authors:  Claire Welsh; Carlos A Celis-Morales; Rosemary Brown; Daniel F Mackay; James Lewsey; Patrick B Mark; Stuart R Gray; Lyn D Ferguson; Jana J Anderson; Donald M Lyall; John G Cleland; Pardeep S Jhund; Jason M R Gill; Jill P Pell; Naveed Sattar; Paul Welsh
Journal:  Circulation       Date:  2019-06-20       Impact factor: 29.690

7.  Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Authors:  Emil Hagström; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Nicolas Danchin; Rafael Diaz; Shaun G Goodman; Robert A Harrington; J Wouter Jukema; Evangelos Liberopoulos; Nikolaus Marx; Jennifer McGinniss; Garen Manvelian; Robert Pordy; Michel Scemama; Harvey D White; Andreas M Zeiher; Gregory G Schwartz
Journal:  Circulation       Date:  2022-06-30       Impact factor: 39.918

Review 8.  Ten things to know about ten cardiovascular disease risk factors ("ASPC Top Ten - 2020").

Authors:  Harold Edward Bays
Journal:  Am J Prev Cardiol       Date:  2020-05-01

Review 9.  Ten things to know about ten cardiovascular disease risk factors.

Authors:  Harold E Bays; Pam R Taub; Elizabeth Epstein; Erin D Michos; Richard A Ferraro; Alison L Bailey; Heval M Kelli; Keith C Ferdinand; Melvin R Echols; Howard Weintraub; John Bostrom; Heather M Johnson; Kara K Hoppe; Michael D Shapiro; Charles A German; Salim S Virani; Aliza Hussain; Christie M Ballantyne; Ali M Agha; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2021-01-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.